Inhalation Sciences assignment in the FORMAMP project on antibiotic resistance is extended by 1,2 MSEK.

Antibiotic resistance is one of the most pressing health concerns on the planet. The EU research project FORMAMP is exploring ways of using Antimicrobial Peptides (AMPs) combined with other nanoformulation strategies, to prevent it. Inhalation Sciences has been contracted to carry out an additional series of studies for the project, extending its role and research revenues.

Inhalation Sciences (ISAB) is being contracted to carry out an additional series of studies during 2017 aiming at characterizing silica particles and assess their potential as an inhaled formulation. The extended research will translate to a maximum of approximately SEK 1,2 MSEK in revenues for ISAB.

FORMAMP is a highly innovative project pioneering new ways of using nanotechnology to formulate and deliver AMPs as a therapy. FORMAMP has already used Inhalation Sciences’ in vitro, ex vivo and in vivo research technology in its project.

ISAB CSO Per Gerde says: “This is a very good project for us. We will be able to provide the required inhalation technology entirely from our in-house methods. I think we are one of the few companies in the world who can deliver the quality of data needed here. We are pleased to contribute to this important cross-disciplinary project. Inhalation technology has an important role to play in peptide research and therapies.”

FORMAMP’s Project Coordinator Dr Lovisa Ringstad says: “We are very excited about the findings from ISAB’s studies related to the project, and the fact that the lung distribution can be measured. This knowledge is highly important in order to design formulations so that the actives are delivered to the right place, which is a prerequisite for treating serious lung infections locally. The contribution from ISAB is extremely valuable for the project. We very much look forward to the results from the additional studies that will be done during the final part of the project.” 

For more information about Inhalation Sciences please contact:

Fredrik Sjövall, CEO 
Phone: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.


The FORMAMP project aims to reduce the drastic increase of resistant bacteria and to develop new and innovative formulation strategies based on the combination of nanotechnology-based delivery systems and antimicrobial peptides (AMPs), for the treatment of infectious diseases caused by bacteria such as Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus (MRSA), and Mycobacterium tuberculosis. FORMAMP is funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no 604182.

The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on November 10, 2017.

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.


Documents & Links